



## **Neuren Engages Burrill & Company to Progress Out-licensing Opportunities**

**19 December 2006:** Neuren Pharmaceuticals Ltd (ASX:NEU) announced today it has engaged Burrill & Company, a San Francisco-based global leader in life sciences whose principal activities are in Venture Capital, Merchant Banking and Media, to advise on out-licensing opportunities for its drug candidates. These include:

- NNZ-2566 (oral) – targeting oral sub-acute brain disease e.g. stroke recovery
- NNZ-4921 – targeting peripheral neuropathy
- NNZ-8000 – targeting breast cancer
- NNZ-3600 – targeting obesity

This will leave Neuren to focus on the clinical development of its lead candidates; Glypromate® as a brain protectant against cognitive impairment following cardiac surgery and cardiac arrest, NNZ-2566 (intravenous) as a therapy for patients that have experienced traumatic brain injury, and NNZ-2591 as an oral treatment for Parkinson's disease and dementia.

Neuren has already received interest in its pipeline from a number of parties. Burrill will work with Neuren to progress the partnering discussions with these companies, as well as others identified by Burrill.

"Neuren has an extensive pipeline of compounds and as we signalled earlier, we are now in a position to begin to realise these opportunities. We have already received some excellent results with all of our drug candidates making them attractive licensing and/or co-development opportunities," said Mr. David Clarke, Chief Executive Officer of Neuren.

### **About Neuren Pharmaceuticals:**

Neuren Pharmaceuticals (ASX: NEU) is a biopharmaceutical company developing novel therapeutics in the fields of brain injury and diseases and metabolic disorders. The Neuren portfolio consists of six product families, targeting markets with large unmet needs and limited competition. Neuren has three lead candidates, Glypromate® and NNZ-2566, presently in clinical trials to treat a range of acute neurological conditions, and NNZ-2591 in preclinical development for Parkinson's and other chronic conditions. Neuren has commercial and development partnerships, including with the US Army Walter Reed Army Institute of Research, Metabolic Pharmaceuticals, UCLA Medical Center and the National Trauma Research Institute in Melbourne.

For more information, please visit Neuren's website at [www.neurenpharma.com](http://www.neurenpharma.com)

### **About Burrill & Company:**

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with principal activities in Venture Capital, Merchant Banking and Media. It has over US\$725 million in venture capital funds under management and has completed numerous merchant banking transactions. Burrill's 50 person scientific and business team, supported by its nearly 40-person Advisory Boards, the strategic and financial network of its limited partners, and the close relationships developed with numerous life science companies and management, provide it with unparalleled access and insight.



Burrill's Media Group publishes an annual book on the "State of the Industry" the 20th Edition is Biotech 2006-Life Sciences: A Changing Prescription. Burrill also publishes a range of biotechnology/life science newsletters and reports and is also the sponsor and facilitator of over a dozen leading industry conferences. Full details may be found at [www.burrillandco.com](http://www.burrillandco.com)

**Contact details:**

<b>Neuren</b>	<b>Media and investor relations</b>
David Clarke CEO T: 1800 259 181 (Australia) T: +64 9 529 3942 (NZ) M: +64 21 988 052	Rebecca Piercy Buchan Consulting T: +61 3 9866 4722 M: +61 422 916 422
<b>Burrill &amp; Company</b>	
Ben Chen Managing Director T: +1 415 591 5441	